ArticleBMC neurology2025
Refractory "status dyskineticus" in a child with post-herpes simplex virus 1 N-methyl-D-aspartate receptor encephalitis: a case report.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell death network regulation in HSV infection: immune evasion versus host defense.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes simplex virus 1 (HSV-1) encephalitis may result in relapsing neurological symptoms secondary to immune-mediated processes, including anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Refractory status dyskineticus (RSD), a severe subset of status dystonicus, is characterized by a hyperkinetic movement disorder phenotype alongside dystonic features. This critical condition presents substantial challenges in neurocritical care. The present case highlights the importance of prompt intervention and immunotherapy escalation in managing severe movement disorders due to pediatric autoimmune encephalitis. CASE PRESENTATION: A previously healthy 2-year-old boy was admitted with HSV-1 encephalitis, confirmed by brain MRI and cerebrospinal fluid (CSF) analysis. When initially treated with acyclovir, the patient achieved partial recovery but later developed encephalopathy, vomiting, behavioral regression, and severe dyskinetic movements. Upon transfer to our center, NMDAR antibodies were detected in the CSF, with no evidence of HSV reactivation. Despite first-line immunotherapy with intravenous steroids and immunoglobulins, his condition deteriorated, progressing to status dyskineticus (SD), with dystonia, hyperthermia, and hypercapnia, requiring intensive care management and mechanical ventilation. A treatment escalation regimen including both immunotherapy with rituximab, rapamycin, bortezomib, and multiple symptomatic therapies resulted in gradual improvement and resolution of the movement disorder.
conclusionsThis case underscores the crucial role of neurocritical care in managing refractory movement disorders associated with autoimmune encephalitis. Early recognition and immunotherapy escalation are essential to improve outcomes in children with complex, life-threatening neurological conditions. A comprehensive, multidisciplinary approach in the neurocritical care setting is key to achieving recovery and minimizing long-term neurological damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.